Academic Journal
The potential value of diagnostic and predictive serum biomarkers for preeclampsia.
| Τίτλος: | The potential value of diagnostic and predictive serum biomarkers for preeclampsia. |
|---|---|
| Συγγραφείς: | Dijmărescu AL; Department of Immunology, Department of Anesthesiology and Intensive Care, University of Medicine and Pharmacy of Craiova, Romania; mihail.boldeanu@umfcv.ro, boldeanumihailvirgil@yahoo.com, mariusnovac2005@yahoo.com., Boldeanu L, Radu M, Rotaru I, Siminel MA, Manolea MM, Vrabie SC, Novac MB, Boldeanu MV, Tănase F |
| Πηγή: | Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie [Rom J Morphol Embryol] 2021 Oct-Dec; Vol. 62 (4), pp. 981-989. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Editura Academiei Române Country of Publication: Romania NLM ID: 9112454 Publication Model: Print Cited Medium: Internet ISSN: 2066-8279 (Electronic) Linking ISSN: 12200522 NLM ISO Abbreviation: Rom J Morphol Embryol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Bucuresti, România : Editura Academiei Române, [1990- |
| Ιατρικοί όροι (MeSH): | Pre-Eclampsia*/diagnosis , Hypertension*, Biomarkers ; Case-Control Studies ; Chemokine CXCL10 ; Female ; Humans ; Matrix Metalloproteinase 13 ; Pregnancy ; Prospective Studies ; Vascular Endothelial Growth Factor A |
| Περίληψη: | Background: Preeclampsia (PE), one of the classes of hypertensive pregnancy disorders, is one of the three causes of maternal morbidity and mortality worldwide. The angiogenic and anti-angiogenic factors are useful markers in predicting and diagnosing PE. Aim: This study aims to detect and measure the serum level of some biomarkers [hypoxia-inducible factor-1 subunit alpha (HIF-1A), vascular endothelial growth factor (VEGF), interferon-gamma-inducible protein of 10 kDa (IP-10), matrix metalloproteinase-13 (MMP-13)] in patients with PE and their correlation with the severity of the disease, to find a good predictor for PE. Patients, Materials and Methods: This prospective study aims to monitor 48 pregnant women who address obstetric consultation and who present risk factors for PE, and a control group with characteristics similar to the study group. Patients were divided into three groups: Group I (n=15) including normal pregnant (NP) women with blood pressure <140∕90 mmHg, without proteinuria, Group II (n=18) including patients with mild PE (MildPE), Group III (n=15) including patients with severe PE (SeverePE). The analysis of serum biomarkers was based on a quantitative sandwich enzyme-linked immunosorbent assay (ELISA), according to the manufacturer's instructions. Results: In our study, we found that all biomarkers investigated have higher concentrations in the serum of patients with SeverePE and MildPE than those in the control subjects (Group I, NP), the concentrations were increasing along with the disease activity. The means concentrations of HIF-1A, VEGF, IP-10, MMP-13, better correlated with indices in SeverePE group than in MildPE group. We found that VEGF was the biomarker that best correlates with indices that assess the severity of PE. The best separation of patients with SeverePE from those with MildPE can be done with the help of MMP-13 (82% accuracy), followed by VEGF (80.40% accuracy) and the least good detection being done by dosing IP-10. Conclusions: We can say that, due to high specificity diagnostic accuracy, determination of serum concentrations of MMP-13 and VEGF, could be useful in the diagnosis and distinguishing of patients with SeverePE and may prove useful in the monitoring of the disease course. |
| References: | J Clin Lab Anal. 2016 Jan;30(1):75-83. (PMID: 25545166) Am J Obstet Gynecol. 2022 Feb;226(2S):S1048-S1058. (PMID: 33002498) Int J Biol Sci. 2020 May 25;16(12):2220-2234. (PMID: 32549767) Placenta. 2010 Jun;31(6):465-74. (PMID: 20359743) J Perinat Med. 2006;34(4):272-9. (PMID: 16856814) Cytokine Growth Factor Rev. 1997 Sep;8(3):207-19. (PMID: 9462486) Am J Physiol Regul Integr Comp Physiol. 2017 Apr 1;312(4):R559-R568. (PMID: 28122716) Rom J Morphol Embryol. 2020 Jul-Sep;61(3):665-672. (PMID: 33817707) Obstet Gynecol. 2013 Nov;122(5):1122-1131. (PMID: 24150027) Pregnancy Hypertens. 2014 Apr;4(2):97-104. (PMID: 26104417) J Matern Fetal Neonatal Med. 2007 Nov;20(11):777-92. (PMID: 17943641) Front Immunol. 2021 Jun 23;12:667841. (PMID: 34248946) J Clin Lab Anal. 2009;23(2):88-92. (PMID: 19288452) BMC Pregnancy Childbirth. 2021 May 8;21(1):364. (PMID: 33964896) Am J Physiol Regul Integr Comp Physiol. 2015 Dec 1;309(11):R1326-43. (PMID: 26447211) Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):1-7. (PMID: 23746796) Hum Reprod Update. 2010 Jul-Aug;16(4):415-31. (PMID: 19926662) Semin Perinatol. 2009 Jun;33(3):130-7. (PMID: 19464502) Circulation. 2011 Mar 22;123(11):1243-62. (PMID: 21325087) Am J Reprod Immunol. 2012 Sep;68(3):258-70. (PMID: 22626009) Am J Physiol Heart Circ Physiol. 2020 Sep 1;319(3):H661-H681. (PMID: 32762557) Virchows Arch. 2018 Apr;472(4):635-642. (PMID: 29426962) Rom J Morphol Embryol. 2018;59(4):1053-1059. (PMID: 30845284) Mol Hum Reprod. 2017 Mar 1;23(3):199-209. (PMID: 28115494) Hypertens Pregnancy. 2016 Nov;35(4):510-519. (PMID: 27322489) Lancet. 2010 Aug 21;376(9741):631-44. (PMID: 20598363) Biomed Res Int. 2017;2017:6432426. (PMID: 28798935) N Engl J Med. 2008 Aug 21;359(8):800-9. (PMID: 18716297) Lancet. 2005 Nov 19;366(9499):1797-803. (PMID: 16298217) Mol Pharmacol. 2006 Nov;70(5):1469-80. (PMID: 16887934) Med Sci Monit. 2019 Sep 15;25:6935-6942. (PMID: 31522187) |
| Substance Nomenclature: | 0 (Biomarkers) 0 (Chemokine CXCL10) 0 (Vascular Endothelial Growth Factor A) EC 3.4.24.- (Matrix Metalloproteinase 13) |
| Entry Date(s): | Date Created: 20220608 Date Completed: 20220609 Latest Revision: 20220722 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9289696 |
| DOI: | 10.47162/RJME.62.4.10 |
| PMID: | 35673817 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2066-8279 |
|---|---|
| DOI: | 10.47162/RJME.62.4.10 |